Kouhei Takashima

Kouhei Takashima

Auto-generated profile, based on publicly available information

Kouhei Takashima

Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ZLZhiyan Silvia Liu
Zhiyan Silvia Liu
SSSayantani Sinha
Sayantani Sinha
MBMaxwell Bannister
Maxwell Bannister
ASAxia Song
Axia Song
EAErica Arriaga-Gomez
Erica Arriaga-Gomez
HNHai Dang Nguyen
Hai Dang Nguyen
RNA splicing factor (SF) gene mutations are commonly observed in patients with myeloid malignancies. Here we showed that SRSF2- and U2AF1-mutant leukemias are preferentially sensitive to PARP inhibitors (PARPi), despite being proficient in homologous recombination repair. Instead, SF-mutant leukemias exhibited R-loop accumulation that elicited an R-loop–associated PARP1 response, rendering cells dependent on PARP1 activity for survival. Consequently, PARPi induced DNA damage and cell death in SF-mutant leukemias in an R-loop-dependent manner. PARPi further increased aberrant R-loop levels, causing higher transcription–replication collisions and triggering ATR activation in SF-mutant leukemias. Ultimately, PARPi-induced DNA damage and cell death in SF-mutant leukemias could be enhanced by ATR inhibition. Finally, the level of PARP1 activity at R-loops correlated with PARPi sensitivity, suggesting that R-loop-associated PARP1 activity could be predictive of PARPi sensitivity in patients harboring SF gene mutations. This study highlights the potential of targeting different R-loop response pathways caused by spliceosome gene mutations as a therapeutic strategy for treating cancer. Significance: Spliceosome-mutant leukemias accumulate R-loops and require PARP1 to resolve transcription–replication conflicts and genomic instability, providing rationale to repurpose FDA-approved PARP inhibitors for patients carrying spliceosome gene mutations.

20 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SGSARAVANAN GANESAN
SARAVANAN GANESAN
RMRebecca M. Murray
Rebecca M. Murray
JSJesus Sotelo
Jesus Sotelo
EEElliot O. Eton
Elliot O. Eton
KTKouhei Takashima
Kouhei Takashima
DLDan A. Landau
Dan A. Landau
Somatic evolution leads to the emergence of clonal diversity across tissues with broad implications for human health. A striking example of somatic evolution is the VEXAS (Vacuoles E1 enzyme X-linked Autoinflammatory Somatic) syndrome, caused by somatic UBA1 mutations in hematopoietic stem cells (HSCs), inducing treatment-refractory, systemic inflammation. However, the mechanisms that lead to survival and expansion of mutant HSCs are unknown, limiting the development of effective therapies. The lack of animal or cellular models of UBA1 -mutant HSCs has hindered such mechanistic understanding, mandating analysis of primary human VEXAS samples, which harbor admixtures of wild-type and UBA1 -mutant HSCs. To address these challenges, we applied single-cell multi-omics to comprehensively define mutant UBA1 -induced transcriptome, chromatin accessibility and signaling pathway alterations in VEXAS patients, allowing for the direct comparison of mutant versus wild-type cells within the same environment. We confirmed the expected enrichment of UBA1 M41V/T mutations in myeloid cells, and additionally discovered that these mutations were also prevalent in Natural Killer (NK) cells in VEXAS patients, providing new insights into disease phenotypes. Through mapping genotypes to molecular phenotypes, including transcriptome, chromatin accessibility, cell surface protein or intracellular protein profiles, in HSCs, we found that UBA1 M41V/T -mutant cells showed an increased inflammation signature (interferon alpha and gamma response pathways), as well as activation of unfolded protein response (UPR) via pro-survival, but not pro-apoptotic, mediators of the PERK pathway, compared to UBA1 wild-type HSCs. Ex vivo validation experiments showed that inhibiting UBA1 in normal CD34+ or using UBA1 -mutant HSCs led to PERK pathway up-regulation, increased myeloid differentiation and cell survival, which was reversed by PERK inhibition. Thus, we demonstrated that human VEXAS HSCs show cell-intrinsic inflammatory phenotypes and survive the proteomic stress caused by compromised ubiquitination through PERK-mediated activation of the UPR. Together, these analyses nominate PERK pathway inhibition as a potential new therapeutic strategy for eradicating the VEXAS-inducing clone, demonstrating the power of single-cell multi-omics profiling of primary patient sample to enable genotype-to-phenotype somatic mapping for the discovery of novel candidates for clinical intervention.

3 July 2025 in Blood
Verified
Journal Article
Closed access
KTKouhei Takashima
Kouhei Takashima
MOMalgorzata Olszewska
Malgorzata Olszewska
VJVrinda Jethalia
Vrinda Jethalia
MSMaria Sirenko
Maria Sirenko
LSLewis Silverman
Lewis Silverman
EPEirini P. Papapetrou
Eirini P. Papapetrou
Myelodysplastic syndromes (MDSs) are myeloid malignancies often driven by mutations in genes encoding splicing factors (SFs). How these mutations drive the clonal expansion of MDS stem/progenitor cells to outcompete normal hematopoietic stem/progenitor cells (HSPCs) remains unexplained. Although a role for inflammatory processes in promoting clonal expansion of mutant HSPCs and MDS pathogenesis has been proposed, the specific mechanisms implicated remain incompletely understood. In this study, using human isogenic induced pluripotent stem cell–based models of SRSF2-mutant MDS and primary cells from patients with MDS, we show that the SRSF2 P95L mutation downregulates basal STAT1 expression. STAT1 downregulation dampens interferon (IFN) signaling in MDS stem/progenitor cells, which, unlike normal HSPCs, show resistance to the suppression of clonogenic ability by IFNs. Treatment with the proteasome inhibitor bortezomib increased STAT1 protein levels and restored the sensitivity of SRSF2-mutant cells to inflammatory stimuli. These results indicate that rewiring of STAT1 signaling by SRSF2 mutations blunts responsiveness to IFNs, conferring clonal fitness to SRSF2-mutant HSPCs against normal HSPCs in the presence of inflammatory stimuli. Our study provides a novel mechanistic link between SF mutations and inflammatory dysregulation and suggests proteasome inhibition as a potential strategy to treat MDS with SRSF2 mutations.

15 February 2024
Verified
Other
Open access
ZLZhiyan Silvia Liu
Zhiyan Silvia Liu
SSSayantani Sinha
Sayantani Sinha
MBMaxwell Bannister
Maxwell Bannister
ASAxia Song
Axia Song
EAErica Arriaga-Gomez
Erica Arriaga-Gomez
HNHai Dang Nguyen
Hai Dang Nguyen
Table S2 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts

15 February 2024
Verified
Other
Open access
ZLZhiyan Silvia Liu
Zhiyan Silvia Liu
SSSayantani Sinha
Sayantani Sinha
MBMaxwell Bannister
Maxwell Bannister
ASAxia Song
Axia Song
EAErica Arriaga-Gomez
Erica Arriaga-Gomez
HNHai Dang Nguyen
Hai Dang Nguyen
Table S1 from R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts

15 February 2024
Verified
Other
Open access
ZLZhiyan Silvia Liu
Zhiyan Silvia Liu
SSSayantani Sinha
Sayantani Sinha
MBMaxwell Bannister
Maxwell Bannister
ASAxia Song
Axia Song
EAErica Arriaga-Gomez
Erica Arriaga-Gomez
HNHai Dang Nguyen
Hai Dang Nguyen
Differential gene expression of K562 U2AF1-WT and U2AF1-S34F cells